Researchers reported an mRNA-based platform that programs mesenchymal stem cells (MSCs) to create an allogeneic cell therapy product dubbed DC-25 with enhanced immunotherapeutic properties. The study demonstrates transient mRNA modifications can overcome immunogenic and functional limits of donor MSCs, enabling standardized off-the-shelf cell therapeutics for cancer and immune disorders. The paper details engineering approaches to boost antigen presentation and antigen-specific stimulation while retaining MSC manufacturing scalability. For clinicians and developers: transient mRNA modification is a niche technical approach that temporarily alters cell function without genomic integration, potentially simplifying regulatory and safety assessments.